Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 94 entries
Sorted by: Best Match Show Resources per page
Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate.

Case reports in transplantation

Belliere J, Guilbeau-Frugier C, Del Bello A, Esposito L, Capuani C, Cardeau-Desangles I, Rostaing L, Kamar N.
PMID: 24963437
Case Rep Transplant. 2014;2014:190516. doi: 10.1155/2014/190516. Epub 2014 May 18.

Belatacept has been found to be efficient at preserving good kidney function in maintenance kidney-transplant patients. Herein, we report on the use of belatacept as a rescue therapy for two kidney-transplant patients presenting with severe adverse events after treatment...

Cite
Belliere J, Guilbeau-Frugier C, Del Bello A, et al. Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate. Case Rep Transplant. 2014;2014:190516doi: 10.1155/2014/190516.
Belliere, J., Guilbeau-Frugier, C., Del Bello, A., Esposito, L., Capuani, C., Cardeau-Desangles, I., Rostaing, L., & Kamar, N. (2014). Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate. Case reports in transplantation, 2014190516. https://doi.org/10.1155/2014/190516
Belliere, Julie, et al. "Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate." Case reports in transplantation vol. 2014 (2014): 190516. doi: https://doi.org/10.1155/2014/190516
Belliere J, Guilbeau-Frugier C, Del Bello A, Esposito L, Capuani C, Cardeau-Desangles I, Rostaing L, Kamar N. Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate. Case Rep Transplant. 2014;2014:190516. doi: 10.1155/2014/190516. Epub 2014 May 18. PMID: 24963437; PMCID: PMC4052196.
Copy Download .nbib Format: NLM
Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates.

Journal of transplantation

Mehawej M, Rostaing L, Alric L, Del Bello A, Izopet J, Kamar N.
PMID: 26257919
J Transplant. 2015;2015:159795. doi: 10.1155/2015/159795. Epub 2015 Jul 16.

Background. There are few data on the combination of (pegylated-) interferon- (Peg-IFN-) α, ribavirin, and first-generation direct-acting antiviral agents (DAAs). Our aim was to describe the efficacy and safety of Peg-IFN-α, ribavirin, and boceprevir in hemodialysis patients. Patients. Six...

Cite
Mehawej M, Rostaing L, Alric L, et al. Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. J Transplant. 2015;2015:159795doi: 10.1155/2015/159795.
Mehawej, M., Rostaing, L., Alric, L., Del Bello, A., Izopet, J., & Kamar, N. (2015). Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of transplantation, 2015159795. https://doi.org/10.1155/2015/159795
Mehawej, Mireille, et al. "Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates." Journal of transplantation vol. 2015 (2015): 159795. doi: https://doi.org/10.1155/2015/159795
Mehawej M, Rostaing L, Alric L, Del Bello A, Izopet J, Kamar N. Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. J Transplant. 2015;2015:159795. doi: 10.1155/2015/159795. Epub 2015 Jul 16. PMID: 26257919; PMCID: PMC4519545.
Copy Download .nbib Format: NLM
Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation.

Case reports in transplantation

Lanfranco L, Joly M, Del Bello A, Esposito L, Cognard N, Perrin P, Moulin B, Kamar N, Caillard S.
PMID: 29445563
Case Rep Transplant. 2017;2017:3197042. doi: 10.1155/2017/3197042. Epub 2017 Dec 28.

Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic microangiopathy (TMA) that were...

Cite
Lanfranco L, Joly M, Del Bello A, et al. Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Rep Transplant. 2017;2017:3197042doi: 10.1155/2017/3197042.
Lanfranco, L., Joly, M., Del Bello, A., Esposito, L., Cognard, N., Perrin, P., Moulin, B., Kamar, N., & Caillard, S. (2017). Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case reports in transplantation, 20173197042. https://doi.org/10.1155/2017/3197042
Lanfranco, Luca, et al. "Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation." Case reports in transplantation vol. 2017 (2017): 3197042. doi: https://doi.org/10.1155/2017/3197042
Lanfranco L, Joly M, Del Bello A, Esposito L, Cognard N, Perrin P, Moulin B, Kamar N, Caillard S. Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Rep Transplant. 2017;2017:3197042. doi: 10.1155/2017/3197042. Epub 2017 Dec 28. PMID: 29445563; PMCID: PMC5763091.
Copy Download .nbib Format: NLM
Genomic Characterization of Dairy Associated .

Frontiers in microbiology

Frantzen CA, Kot W, Pedersen TB, Ardö YM, Broadbent JR, Neve H, Hansen LH, Dal Bello F, Østlie HM, Kleppen HP, Vogensen FK, Holo H.
PMID: 28217118
Front Microbiol. 2017 Feb 03;8:132. doi: 10.3389/fmicb.2017.00132. eCollection 2017.

Undefined mesophilic mixed (DL-type) starter cultures are composed of predominantly

Cite
Frantzen CA, Kot W, Pedersen TB, et al. Genomic Characterization of Dairy Associated . Front Microbiol. 2017;8:132doi: 10.3389/fmicb.2017.00132.
Frantzen, C. A., Kot, W., Pedersen, T. B., Ardö, Y. M., Broadbent, J. R., Neve, H., Hansen, L. H., Dal Bello, F., Østlie, H. M., Kleppen, H. P., Vogensen, F. K., & Holo, H. (2017). Genomic Characterization of Dairy Associated . Frontiers in microbiology, 8132. https://doi.org/10.3389/fmicb.2017.00132
Frantzen, Cyril A, et al. "Genomic Characterization of Dairy Associated ." Frontiers in microbiology vol. 8 (2017): 132. doi: https://doi.org/10.3389/fmicb.2017.00132
Frantzen CA, Kot W, Pedersen TB, Ardö YM, Broadbent JR, Neve H, Hansen LH, Dal Bello F, Østlie HM, Kleppen HP, Vogensen FK, Holo H. Genomic Characterization of Dairy Associated . Front Microbiol. 2017 Feb 03;8:132. doi: 10.3389/fmicb.2017.00132. eCollection 2017. PMID: 28217118; PMCID: PMC5289962.
Copy Download .nbib Format: NLM
Multi-Analyte MS Based Investigation in Relation to the Illicit Treatment of Fish Products with Hydrogen Peroxide.

Toxics

Dal Bello F, Aigotti R, Zorzi M, Giaccone V, Medana C.
PMID: 31936204
Toxics. 2020 Jan 08;8(1). doi: 10.3390/toxics8010002.

Fishery products are perishable due to the action of many enzymes, both endogenous and exogenous. The latter are produced by bacteria that may contaminate the products. When fishes age, there is a massive bacteria growth that causes the appearance...

Cite
Dal Bello F, Aigotti R, Zorzi M, et al. Multi-Analyte MS Based Investigation in Relation to the Illicit Treatment of Fish Products with Hydrogen Peroxide. Toxics. 2020;8(1)doi: 10.3390/toxics8010002.
Dal Bello, F., Aigotti, R., Zorzi, M., Giaccone, V., & Medana, C. (2020). Multi-Analyte MS Based Investigation in Relation to the Illicit Treatment of Fish Products with Hydrogen Peroxide. Toxics, 8(1), . https://doi.org/10.3390/toxics8010002
Dal Bello, Federica, et al. "Multi-Analyte MS Based Investigation in Relation to the Illicit Treatment of Fish Products with Hydrogen Peroxide." Toxics vol. 8,1 (2020). doi: https://doi.org/10.3390/toxics8010002
Dal Bello F, Aigotti R, Zorzi M, Giaccone V, Medana C. Multi-Analyte MS Based Investigation in Relation to the Illicit Treatment of Fish Products with Hydrogen Peroxide. Toxics. 2020 Jan 08;8(1). doi: 10.3390/toxics8010002. PMID: 31936204; PMCID: PMC7151737.
Copy Download .nbib Format: NLM
A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients.

Kidney international reports

Kamar N, Lepage B, Couzi L, Albano L, Durrbach A, Pernin V, Esposito L, Hebral AL, Darres A, Lequintrec M, Cassuto E, Merville P, Congy N, Del Bello A.
PMID: 32775820
Kidney Int Rep. 2020 Jun 02;5(8):1207-1217. doi: 10.1016/j.ekir.2020.05.020. eCollection 2020 Aug.

BACKGROUND: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly sensitized kidney-transplant patients given polyclonal antibodies compared with those given anti-CD25 monoclonal antibodies.METHODS: This...

Cite
Kamar N, Lepage B, Couzi L, et al. A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. Kidney Int Rep. 2020;5(8):1207-1217doi: 10.1016/j.ekir.2020.05.020.
Kamar, N., Lepage, B., Couzi, L., Albano, L., Durrbach, A., Pernin, V., Esposito, L., Hebral, A. L., Darres, A., Lequintrec, M., Cassuto, E., Merville, P., Congy, N., & Del Bello, A. (2020). A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. Kidney international reports, 5(8), 1207-1217. https://doi.org/10.1016/j.ekir.2020.05.020
Kamar, Nassim, et al. "A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients." Kidney international reports vol. 5,8 (2020): 1207-1217. doi: https://doi.org/10.1016/j.ekir.2020.05.020
Kamar N, Lepage B, Couzi L, Albano L, Durrbach A, Pernin V, Esposito L, Hebral AL, Darres A, Lequintrec M, Cassuto E, Merville P, Congy N, Del Bello A. A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. Kidney Int Rep. 2020 Jun 02;5(8):1207-1217. doi: 10.1016/j.ekir.2020.05.020. eCollection 2020 Aug. PMID: 32775820; PMCID: PMC7403559.
Copy Download .nbib Format: NLM
Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation.

Frontiers in pharmacology

Del Bello A, Gaible C, Longlune N, Hebral AL, Esposito L, Gandia P, Kamar N.
PMID: 34690747
Front Pharmacol. 2021 Oct 07;12:602764. doi: 10.3389/fphar.2021.602764. eCollection 2021.

No abstract available.

Cite
Del Bello A, Gaible C, Longlune N, et al. Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. Front Pharmacol. 2021;12:602764doi: 10.3389/fphar.2021.602764.
Del Bello, A., Gaible, C., Longlune, N., Hebral, A. L., Esposito, L., Gandia, P., & Kamar, N. (2021). Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. Frontiers in pharmacology, 12602764. https://doi.org/10.3389/fphar.2021.602764
Del Bello, Arnaud, et al. "Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation." Frontiers in pharmacology vol. 12 (2021): 602764. doi: https://doi.org/10.3389/fphar.2021.602764
Del Bello A, Gaible C, Longlune N, Hebral AL, Esposito L, Gandia P, Kamar N. Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. Front Pharmacol. 2021 Oct 07;12:602764. doi: 10.3389/fphar.2021.602764. eCollection 2021. PMID: 34690747; PMCID: PMC8529208.
Copy Download .nbib Format: NLM
Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssière L, Izopet J, Kamar N.
PMID: 34331842
Am J Transplant. 2021 Jul 31; doi: 10.1111/ajt.16775. Epub 2021 Jul 31.

No abstract available.

Cite
Del Bello A, Abravanel F, Marion O, et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2021;doi: 10.1111/ajt.16775.
Del Bello, A., Abravanel, F., Marion, O., Couat, C., Esposito, L., Lavayssière, L., Izopet, J., & Kamar, N. (2021). Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, . https://doi.org/10.1111/ajt.16775
Del Bello, Arnaud, et al. "Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients." American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. (2021). doi: https://doi.org/10.1111/ajt.16775
Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssière L, Izopet J, Kamar N. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2021 Jul 31; doi: 10.1111/ajt.16775. Epub 2021 Jul 31. PMID: 34331842; PMCID: PMC8441706.
Copy Download .nbib Format: NLM
Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssière L, Izopet J, Kamar N.
PMID: 34331842
Am J Transplant. 2022 Jan;22(1):322-323. doi: 10.1111/ajt.16775. Epub 2021 Aug 31.

No abstract available.

Cite
Del Bello A, Abravanel F, Marion O, et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2021;22(1):322-323doi: 10.1111/ajt.16775.
Del Bello, A., Abravanel, F., Marion, O., Couat, C., Esposito, L., Lavayssière, L., Izopet, J., & Kamar, N. (2022). Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 22(1), 322-323. https://doi.org/10.1111/ajt.16775
Del Bello, Arnaud, et al. "Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients." American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. 22,1 (2022): 322-323. doi: https://doi.org/10.1111/ajt.16775
Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssière L, Izopet J, Kamar N. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2022 Jan;22(1):322-323. doi: 10.1111/ajt.16775. Epub 2021 Aug 31. PMID: 34331842; PMCID: PMC8441706.
Copy Download .nbib Format: NLM
Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator.

Physics and imaging in radiation oncology

Stark LS, Andratschke N, Baumgartl M, Bogowicz M, Chamberlain M, Dal Bello R, Ehrbar S, Girbau Garcia Z, Guckenberger M, Krayenbühl J, Pouymayou B, Rudolf T, Vuong D, Wilke L, Zamburlini M, Tanadini-Lang S.
PMID: 33458353
Phys Imaging Radiat Oncol. 2020 Nov 08;16:109-112. doi: 10.1016/j.phro.2020.09.013. eCollection 2020 Oct.

The introduction of real-time imaging by magnetic resonance guided linear accelerators (MR-Linacs) enabled adaptive treatments and gating on the tumor position. Different end-to-end tests monitored the accuracy of our MR-Linac during the first year of clinical operation. We report...

Cite
Stark LS, Andratschke N, Baumgartl M, et al. Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator. Phys Imaging Radiat Oncol. 2020;16:109-112doi: 10.1016/j.phro.2020.09.013.
Stark, L. S., Andratschke, N., Baumgartl, M., Bogowicz, M., Chamberlain, M., Dal Bello, R., Ehrbar, S., Girbau Garcia, Z., Guckenberger, M., Krayenbühl, J., Pouymayou, B., Rudolf, T., Vuong, D., Wilke, L., Zamburlini, M., & Tanadini-Lang, S. (2020). Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator. Physics and imaging in radiation oncology, 16109-112. https://doi.org/10.1016/j.phro.2020.09.013
Stark, Luisa S, et al. "Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator." Physics and imaging in radiation oncology vol. 16 (2020): 109-112. doi: https://doi.org/10.1016/j.phro.2020.09.013
Stark LS, Andratschke N, Baumgartl M, Bogowicz M, Chamberlain M, Dal Bello R, Ehrbar S, Girbau Garcia Z, Guckenberger M, Krayenbühl J, Pouymayou B, Rudolf T, Vuong D, Wilke L, Zamburlini M, Tanadini-Lang S. Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator. Phys Imaging Radiat Oncol. 2020 Nov 08;16:109-112. doi: 10.1016/j.phro.2020.09.013. eCollection 2020 Oct. PMID: 33458353; PMCID: PMC7807549.
Copy Download .nbib Format: NLM
Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications.

Free radical biology & medicine

Felicetti F, Aimaretti E, Dal Bello F, Gatti F, Godono A, Saba F, Einaudi G, Collino M, Fagioli F, Aragno M, Brignardello E.
PMID: 34856327
Free Radic Biol Med. 2021 Nov 30;178:76-82. doi: 10.1016/j.freeradbiomed.2021.11.036. Epub 2021 Nov 30.

Hodgkin lymphoma (HL) is today one of the most curable pediatric cancers. Despite survival rates now exceeding 90%, survivors of pediatric HL are still at higher risk to develop late effects of cancer therapy. Premature aging has been proposed...

Cite
Felicetti F, Aimaretti E, Dal Bello F, et al. Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications. Free Radic Biol Med. 2021;178:76-82doi: 10.1016/j.freeradbiomed.2021.11.036.
Felicetti, F., Aimaretti, E., Dal Bello, F., Gatti, F., Godono, A., Saba, F., Einaudi, G., Collino, M., Fagioli, F., Aragno, M., & Brignardello, E. (2021). Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications. Free radical biology & medicine, 17876-82. https://doi.org/10.1016/j.freeradbiomed.2021.11.036
Felicetti, Francesco, et al. "Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications." Free radical biology & medicine vol. 178 (2021): 76-82. doi: https://doi.org/10.1016/j.freeradbiomed.2021.11.036
Felicetti F, Aimaretti E, Dal Bello F, Gatti F, Godono A, Saba F, Einaudi G, Collino M, Fagioli F, Aragno M, Brignardello E. Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications. Free Radic Biol Med. 2021 Nov 30;178:76-82. doi: 10.1016/j.freeradbiomed.2021.11.036. Epub 2021 Nov 30. PMID: 34856327.
Copy Download .nbib Format: NLM
Management of anastomotic biliary stricture after liver transplantation and impact on survival.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Jarlot-Gas C, Muscari F, Mokrane FZ, Del Bello A, Culetto A, Buscail E, Péré G, Fares N, Péron JM, Cuellar E, Barange K, Kamar N, Suc B, Maulat C.
PMID: 33423950
HPB (Oxford). 2021 Aug;23(8):1259-1268. doi: 10.1016/j.hpb.2020.12.008. Epub 2020 Dec 26.

BACKGROUND: Anastomotic biliary strictures (AS) is the main surgical complication after liver transplantation. The aims of this study are to investigate the risk factors of AS, its management and its impact on overall survival and survival of the graft.METHODS:...

Cite
Jarlot-Gas C, Muscari F, Mokrane FZ, et al. Management of anastomotic biliary stricture after liver transplantation and impact on survival. HPB (Oxford). 2020;23(8):1259-1268doi: 10.1016/j.hpb.2020.12.008.
Jarlot-Gas, C., Muscari, F., Mokrane, F. Z., Del Bello, A., Culetto, A., Buscail, E., Péré, G., Fares, N., Péron, J. M., Cuellar, E., Barange, K., Kamar, N., Suc, B., & Maulat, C. (2021). Management of anastomotic biliary stricture after liver transplantation and impact on survival. HPB : the official journal of the International Hepato Pancreato Biliary Association, 23(8), 1259-1268. https://doi.org/10.1016/j.hpb.2020.12.008
Jarlot-Gas, Cécile, et al. "Management of anastomotic biliary stricture after liver transplantation and impact on survival." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. 23,8 (2021): 1259-1268. doi: https://doi.org/10.1016/j.hpb.2020.12.008
Jarlot-Gas C, Muscari F, Mokrane FZ, Del Bello A, Culetto A, Buscail E, Péré G, Fares N, Péron JM, Cuellar E, Barange K, Kamar N, Suc B, Maulat C. Management of anastomotic biliary stricture after liver transplantation and impact on survival. HPB (Oxford). 2021 Aug;23(8):1259-1268. doi: 10.1016/j.hpb.2020.12.008. Epub 2020 Dec 26. PMID: 33423950.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 94 entries